This Article Full Text (PDF) A correction has been published References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (7) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Dunbar, G. C. Articles by Wamsley, J. Search for Related Content PubMed PubMed Citation Articles by Dunbar, G. C. Articles by Wamsley, J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Memory Social Bookmarking                         What's this?

Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI)

Clinical Development and Regulatory Affairs, Targacept Inc., Winston Salem, USA

Fraser Inglis

Glasgow Memory Clinic, Golden Jubilee National Hospital, Glasgow, UK

Ramana Kuchibhatla

Clinical Development and Regulatory Affairs, Targacept Inc., Winston Salem, USA

Tonmoy Sharma

Clinical Neuroscience Research Centre, Dartford, UK

Mark Tomlinson

Sequani Clinical, Ledbury, UK

James Wamsley

Clinical Development and Regulatory Affairs, Targacept Inc., Winston Salem, USA

Cognitive decline seen in the normal elderly is associated with selective loss of neuronal nicotinic acetylcholine receptors (nAChRs). Nicotine given either by inhalation or transdermally helps cognition, but unacceptable side effects limit its utility. The present study assessed the safety, tolerability and effect on cognition of ispronicline, a highly selective partial agonist at the 4ß2 nAChR, in elderly subjects (n =76) with age associated memory impairment (AAMI). This double-blind, placebo-controlled cross-over study explored ascending oral doses of ispronicline in the range 50–150mg given as a single morning dose for a period of 3 weeks. Pharmacokinetics (PK) were assessed, as well as cognitive function measured by means of the Cognitive Drug Research (CDR) computerized test battery. Ispronicline had a favourable safety profile and was well tolerated at doses below 150mg. No effect of clinical importance was seen on biochemistry, haematology, urine analysis, vital signs, electrocardiogram (ECG) or Holter monitoring. The most frequent drug induced adverse event was light-headedness (dizziness). A beneficial effect was seen on cognition across the dose range. This was most marked at 50mg on factors measuring attention and episodic memory. PK analysis indicated a plasma Cmax range of 5–25/35ng/ml ispronicline was associated with the most beneficial effect. These early results demonstrate ispronicline was well tolerated and did not display the side effects typical of nicotine. Ispronicline also had a beneficial effect on cognition in subjects with AAMI. This was seen most strongly in a Cmax range that had been predicted from pre-clinical animal studies.

Key Words: ispronicline • age associated memory impairment • cognition • neuronal nicotinic acetylcholine receptor

Journal of Psychopharmacology, Vol. 21, No. 2, 171-178 (2007)
DOI: 10.1177/0269881107066855


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Goudie and J. Cole Switching antipsychotics. Antipsychotic tolerance, withdrawal and relapse: unresolved issues and research implications J Psychopharmacol, September 1, 2008; 22(7): 815 - 817. [PDF]